NCBiotech News

North Carolina has been recognized by Merchant Maverick as one of the top10 states in the country for women-led startups.

The 20th edition of World Stem Cell Summit will be held in Winston-Salem June 5-9, 2023, in conjunction with the 10th annual Regenerative Medicine Essentials Course.

New York immunotherapy company Immunaeon is the latest firm to establish a presence in Winston-Salem’s growing regenerative medicine community, marketed as the RegenMed Hub.

Winston-Salem is adding three healthcare diagnostics companies and a new clinical trials program to its growing regenerative medicine community, marketed as the RegenMed Hub.

Eva Garland, Jessica Neil and Laura Potter are three outstanding life sciences leaders who are among the 25 awardees of the Triangle Business Journal 2023 Women in Business Awards.

Raleigh biopharma company FLAG Therapeutics has achieved a milestone with an FDA Rare Pediatric Disease designation for the company’s investigational treatment for a rare brain tumor in children.

Ag tech pioneers Calyxt and Cibus have entered into a definitive merger agreement under which they will merge in an all-stock transaction.

RTP-based medical device company Asensus says the expansion of machine vision capabilities to its previously cleared Senhance ISU has just received CE Mark, a European Union regulatory approval for medical devices.

Global pharmaceutical giant Eli Lilly is investing another $450 million and adding at least 100 jobs in an expansion of its nearly completed $474 million Research Triangle Park pharmaceutical manufacturing campus.

Durham pharmaceutical company Eppin Pharma has secured an investment of up to $800,000 from the Male Contraceptive Initiative, a national nonprofit also based in Durham, to help initiate clinical trials for its male birth-control pill.

Oerth Bio, an agricultural biotechnology company in downtown Durham, and Bayer, a global enterprise focused on health care and nutrition, announce a new collaboration and celebrate Oerth’s facilities expansion.

Imagine receiving a COVID-19 vaccine not from the jab of a needle and syringe but by slipping a thin, clear film smaller than a postage stamp inside your cheek or under your tongue and letting it dissolve.

RTP-based Pathalys Pharma has secured $150 million in new financing to support Phase 3 clinical trials for its leading drug candidate to treat end-stage kidney disease.

RTP-based Innatrix is seeking more funding to help it develop its environmentally friendly technology using peptides as a targeted way of controlling agricultural diseases and pests that can devastate crops.

Paris-based Cellectis has successfully dosed its first U.S. patient with its UCART22 allogeneic CAR T-cell therapy product candidate that it made in its new Raleigh facility.